Oncothyreon (ONTY) Reports Strong Data for ONT-10 and PX-866

April 4, 2011 6:53 AM EDT
Oncothyreon Inc. (Nasdaq: ONTY) presents positive data for ONT-10 and PX-866.

From the release:

"ONT-10 produced a robust antibody response in mice that was specific for human tumor MUC1. A strong cellular immune response directed to the target was also shown. ONT-10 blocked the growth of two different tumors expressing human MUC1 in murine models, with a high proportion of animals tumor free at the conclusion of the experiment.

Additionally, data presented at the meeting concerned the efficacy of PX-866 alone or in combination with either docetaxel or cetuximab in direct patient human tumor xenograft models (DPTM) of squamous cell carcinoma of the head and neck (SCCHN) developed by Dr. Antonio Jimeno's laboratory at University of Colorado School of Medicine. These models maintain the histology of the tumor and are particularly suited to preclinical evaluation of novel cancer therapeutics. PX-866 was equal or superior to docetaxel in slowing tumor growth in two of four DPTM and equal or superior to cetuximab in each of four DPTM."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment